title: Cardiac biointerventions: whatever happened to stem cell and gene therapy?
abstract: Angiogenic gene therapy and stem cell administration represent two "biologic" interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these "biointerventions" may be expected in the near future.
authors.affiliation: Division of Cardiothoracic Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook, NY 11794-8020, USA. todd.rosengart@stonybrookmedicine.edu
authors.forename: Todd K
authors.initials: TK
authors.lastname: Rosengart
authors.forename: Eleanor
authors.initials: E
authors.lastname: Fallon
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Crystal
mesh_terms: D015316:Genetic Therapy; D006331:Heart Diseases / Q000628:therapy*; D006801:Humans; D033581:Stem Cell Transplantation